Indication-Based Pricing Hurdle A Block For Roche's Ocrevus In UK
Executive Summary
The UK's National Institute for Health and Care Excellence rejected Roche's ocrelizumab for provision to adults with primary progressive multiple sclerosis due to cost grounds and efficacy uncertainties - but observers expect a compromise to be eventually struck.
You may also be interested in...
MediciNova's Ibudilast Shows Potential In Progressive MS
The only approved treatment for primary progressive MS is Roche's Ocrevus but there is a possible competitor on the horizon following promising Phase II data which showed that ibudilast slowed brain shrinkage by nearly half.
Discounts Help Prompt UK’s NICE Turnaround on Dupixent and Ocrevus
After initially saying no, the UK health technology appraisal body, NICE, has recommended for use on the National Health Service Sanofi/Regeneron’s Dupixent and Roche’s Ocrevus. Confidential discounts helped convince NICE.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.